Dr. Kumar’s Take
This was a small phase I safety trial in nine people with stage IV pancreatic cancer, testing high dose intravenous vitamin C given alongside standard gemcitabine chemotherapy. The point of a phase I study is tolerability, not proof of benefit, and on that measure the combination held up: side effects attributable to the drug combination were rare and dose limiting criteria were never met. The authors describe the early data as suggesting some efficacy, and I read that the way they framed it, as a reason to run a larger trial rather than a result to act on.
Key Takeaways
✔ High-dose IV vitamin C (15 to 125 g twice weekly) with gemcitabine met no dose-limiting criteria.
✔ Adverse events attributable to the combination were rare: diarrhea in 4 subjects and dry mouth in 6.
✔ Mean survival among subjects who completed at least 2 cycles (8 weeks) of therapy was 13 ± 2 months.
✔ Trough plasma ascorbate rose from 0.78 ± 0.09 to 1.46 ± 0.02 mg/dL (44 to 83 µM, p < 0.001).
Actionable tip
Ask your healthcare team about ongoing trials of high-dose vitamin C infusions alongside chemotherapy to see if you might qualify.
Brief Summary
A phase I clinical trial enrolled nine subjects with biopsy-proven stage IV pancreatic adenocarcinoma. Each received intravenous ascorbate twice weekly, dosed from 15 g to 125 g using Simon’s accelerated titration design, with the goal of reaching a post-infusion plasma level of at least 350 mg/dL (20 mM). Gemcitabine was given concurrently. The investigators tracked disease burden, weight, performance status, hematologic and metabolic labs, time to progression, and overall survival. Dose-limiting criteria were not met, and the authors concluded that pharmacologic ascorbate given with gemcitabine is well tolerated.
Study Design
- Nine subjects with biopsy-proven stage IV pancreatic adenocarcinoma
- IV ascorbate twice weekly, 15 g to 125 g, escalated by Simon’s accelerated titration design
- Target post-infusion plasma ascorbate of at least 350 mg/dL, equal to 20 mM
- Concurrent gemcitabine
- Monitoring of disease burden, weight, performance status, hematologic and metabolic labs, time to progression, and overall survival
Results
- Dose-limiting criteria were not met in this study
- Adverse events attributable to the drug combination were rare: diarrhea in 4 subjects, dry mouth in 6
- Mean plasma ascorbate trough levels were significantly higher than baseline, 1.46 ± 0.02 versus 0.78 ± 0.09 mg/dL, equal to 83 versus 44 µM (p < 0.001)
- Mean survival of subjects completing at least 2 cycles (8 weeks) of therapy was 13 ± 2 months
How High-Dose Vitamin C Supports Cancer Treatment
Ascorbate can act as an antioxidant or a pro-oxidant, and in the presence of catalytic metals it typically behaves as a pro-oxidant. Pharmacological ascorbate means using high intravenous doses to reach plasma levels on the order of 100 to 1000 times healthy nutritional levels. At those levels it has been proposed to act as a pro-drug that delivers hydrogen peroxide to tumors, and at doses achievable in humans it selectively kills pancreatic cancer cells through that hydrogen peroxide mediated mechanism. Preclinical data also indicate that adding pharmacological ascorbate to the standard gemcitabine regimen may improve outcomes, which is the rationale this trial was built on.
Related Studies and Research
Vitamin C Redox and Brain Health: Metabolism and Redox State in the Brain: Reviews ascorbate’s neuronal redox regulation and support of neurotransmitter synthesis.
Regulation of Collagen Synthesis by Ascorbic Acid: Chronicles how vitamin C facilitates collagen biosynthesis through enzymatic hydroxylation.
High-Dose Intravenous Vitamin C with Chemotherapy in Ovarian Cancer: Demonstrates improved chemosensitivity in ovarian cancer with parenteral ascorbate.
Potential Mechanisms of Action for Vitamin C in Cancer: Reviewing the Evidence: Explores ascorbate’s impact on cancer cell redox homeostasis and apoptosis pathways.
Role of Vitamin C in Carnitine Biosynthesis: Highlights ascorbate’s coenzyme role in converting trimethyllysine to carnitine for energy metabolism.
Frequently Asked Questions
What is pharmacological ascorbate?
It is the use of high doses of vitamin C given intravenously to reach plasma levels roughly 100 to 1000 times higher than healthy nutritional levels.
Does high-dose vitamin C replace chemotherapy?
No. In this trial ascorbate was given concurrently with gemcitabine, not instead of it. It was not tested on its own.
Are there serious side effects of IV vitamin C?
In this trial, adverse events attributable to the drug combination were rare, and the most common were diarrhea and dry mouth. Dose-limiting criteria were not met.
How can I find a trial using vitamin C and chemotherapy?
Search clinicaltrials.gov for terms like “ascorbate” and “gemcitabine,” or ask your oncologist if any local trials are open.
Conclusion
This phase I trial suggests pharmacologic ascorbate can be given concurrently with gemcitabine and is well tolerated. The authors call the efficacy signal from this small sample initial, and say further studies powered to determine efficacy should be conducted.
